Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 312.50 | 200.50 | 124.00 | 313.25 | 0.3959 | -0.5260 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 296.00 | 313.25 | 0.9449 | 0.8315 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 287.00 | 313.25 | 0.9162 | 0.7458 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 312.50 | 200.50 | 301.00 | 313.25 | 0.9609 | 0.8798 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 305.00 | 313.25 | 0.9737 | 0.9188 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 349.00 | 313.25 | 1.1141 | 1.3656 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 312.50 | 200.50 | 380.00 | 313.25 | 1.2131 | 1.7000 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 280.00 | 313.25 | 0.8939 | 0.6801 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 312.50 | 200.50 | 146.00 | 313.25 | 0.4661 | -0.3891 |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 190.00 | 313.25 | 0.6065 | -0.0802 |
| SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 312.50 | 200.50 | 321.00 | 313.25 | 1.0247 | 1.0774 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 378.00 | 313.25 | 1.2067 | 1.6779 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 312.50 | 200.50 | 369.00 | 313.25 | 1.1780 | 1.5795 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 312.50 | 200.50 | 194.00 | 313.25 | 0.6193 | -0.0499 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 9 | 312.50 | 200.50 | 231.00 | 313.25 | 0.7374 | 0.2461 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 432.00 | 313.25 | 1.3791 | 2.2952 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 340.00 | 313.25 | 1.0854 | 1.2715 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 312.50 | 200.50 | 399.00 | 313.25 | 1.2737 | 1.9126 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 312.50 | 200.50 | 239.00 | 313.25 | 0.7630 | 0.3137 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 268.00 | 313.25 | 0.8556 | 0.5695 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 351.00 | 313.25 | 1.1205 | 1.3867 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 312.50 | 200.50 | 158.00 | 313.25 | 0.5044 | -0.3093 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 412.00 | 313.25 | 1.3152 | 2.0613 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 368.00 | 313.25 | 1.1748 | 1.5687 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 422.00 | 313.25 | 1.3472 | 2.1775 |